Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model.

Journal for immunotherapy of cancer·2026
Same author

Post-Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation.

European journal of haematology·2026
Same author

TIGIT Blockade Potentiates the Anti-Leukemic Activity of Exercise-Mobilized Donor Lymphocytes and Expanded γδ T-Cells.

Cancers·2026
Same author

Exercise-mobilized lymphocytes enhance antibody-based immunotherapy in multiple myeloma through CD16<sup>+</sup> NK cell-mediated cytotoxicity.

Journal of translational medicine·2026
Same author

Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia.

Blood advances·2026
Same author

Isoproterenol infusion enhances composition and function of G-CSF mobilized allogeneic peripheral blood hematopoietic cell grafts.

Stem cell research & therapy·2025
Same journal

Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity.

Oncoimmunology·2026
Same journal

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Oncoimmunology·2026
Same journal

Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.

Oncoimmunology·2026
Same journal

Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.

Oncoimmunology·2026
Same journal

Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.

Oncoimmunology·2026
Same journal

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.

Oncoimmunology·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K

Targeted immunotherapy for pediatric solid tumors.

Lisa M Kopp1, Emmanuel Katsanis1

  • 1Division of Hematology, Oncology, BMT, Department of Pediatrics, University of Arizona , Tucson, Ariz, USA.

Oncoimmunology
|May 4, 2016
PubMed
Summary
This summary is machine-generated.

Pediatric solid tumors that have spread or resist treatment still have poor outcomes. Promising targeted immunotherapies are improving survival for these aggressive childhood cancers.

Keywords:
Immunotherapypediatric oncologysolid tumors

More Related Videos

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.7K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

4.4K

Related Experiment Videos

Last Updated: Mar 21, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K
Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.7K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

4.4K

Area of Science:

  • Pediatric Oncology
  • Cancer Immunology
  • Translational Medicine

Background:

  • Metastatic and refractory pediatric solid tumors represent a significant clinical challenge with historically poor prognoses.
  • Despite high cure rates in many pediatric cancers, a subset of aggressive solid tumors remains difficult to treat.
  • Advances in understanding tumor immunology are crucial for developing novel therapeutic strategies.

Approach:

  • This review synthesizes current research on targeted immunotherapeutic approaches for pediatric solid tumors.
  • We examine the mechanisms of action and clinical efficacy of emerging immunotherapies.
  • The focus is on strategies showing promise in preclinical and early-phase clinical trials.

Key Points:

  • Targeted immunotherapies are demonstrating a significant impact on treatment and survival rates for aggressive pediatric solid tumors.
  • Specific immune checkpoint inhibitors and adoptive cell therapies are among the most promising avenues.
  • Personalized immunotherapy approaches based on tumor-specific antigens are under investigation.

Conclusions:

  • Immunotherapy offers a new frontier in treating pediatric solid tumors that are metastatic or refractory to conventional therapies.
  • Continued research and clinical trials are essential to optimize the use of these novel agents in pediatric oncology.
  • Targeted immunotherapeutic strategies hold the potential to improve long-term outcomes for children with high-risk solid tumors.